Biosynex
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more
Biosynex (ALBIO) - Total Liabilities
Latest total liabilities as of June 2025: €105.13 Million EUR
Based on the latest financial reports, Biosynex (ALBIO) has total liabilities worth €105.13 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biosynex - Total Liabilities Trend (2006–2024)
This chart illustrates how Biosynex's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biosynex Competitors by Total Liabilities
The table below lists competitors of Biosynex ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sintex Plastics Technology Limited
NSE:SPTL
|
India | ₹206.50 Million |
|
Doubledown Interactive Co Ltd
NASDAQ:DDI
|
USA | $90.13 Million |
|
Khadim India Limited
NSE:KHADIM
|
India | ₹4.10 Billion |
|
Bio Green Energy Tech PCL
BK:BIOTEC
|
Thailand | ฿1.17 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Biosynex's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosynex's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosynex (2006–2024)
The table below shows the annual total liabilities of Biosynex from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €114.19 Million | -2.74% |
| 2023-12-31 | €117.41 Million | +25.96% |
| 2022-12-31 | €93.21 Million | -7.84% |
| 2021-12-31 | €101.14 Million | +69.17% |
| 2020-12-31 | €59.78 Million | +252.37% |
| 2019-12-31 | €16.97 Million | +66.35% |
| 2018-12-31 | €10.20 Million | -12.10% |
| 2017-12-31 | €11.60 Million | -23.39% |
| 2016-12-31 | €15.15 Million | +122.01% |
| 2015-12-31 | €6.82 Million | +103.94% |
| 2014-12-31 | €3.35 Million | -0.24% |
| 2013-12-31 | €3.35 Million | -8.63% |
| 2012-12-31 | €3.67 Million | +297.02% |
| 2011-12-31 | €924.34K | -1.96% |
| 2010-12-31 | €942.86K | -2.39% |
| 2009-12-31 | €965.95K | +32.14% |
| 2008-12-31 | €731.01K | +47.38% |
| 2007-12-31 | €496.00K | +16.98% |
| 2006-12-31 | €424.00K | -- |